SCHEMBL4701423

SCHEMBL4701423

CN1C(=O)C(NC(=O)OCc2ccccc2)N=C(c2ccc(C(N)=O)cc2)c2ccccc21

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 1/20 0.67
SENP1 Q9P0U3 2/20 0.62
CCKBR P32239 9/20 0.61
KCNH2 Q12809 1/20 0.61
PSEN1 P49768 1/20 0.59
PSEN2 P49810 1/20 0.59
APH1B Q8WW43 1/20 0.59
NCSTN Q92542 1/20 0.59
APH1A Q96BI3 1/20 0.59
PSENEN Q9NZ42 1/20 0.59
BRD4 O60885 3/20 0.57
BRD2 P25440 3/20 0.57
BRD3 Q15059 3/20 0.57
CCKAR P32238 4/20 0.57
GABRP O00591 1/20 0.57
GABRD O14764 1/20 0.57
GABRA1 P14867 1/20 0.57
GABRB1 P18505 1/20 0.57
GABRG2 P18507 1/20 0.57
GABRB3 P28472 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3788080 0.92 SCN9A (0.78) SCN9ASENP1CCKBRKCNH2BRD4
SCHEMBL6993452 0.92 SCN9A (0.78) SCN9ASENP1CCKBRKCNH2BRD4
SCHEMBL4697564 0.89 SCN9A (0.69) SCN9ASENP1CCKBRKCNH2BRD4
SCHEMBL4420621 0.89 SCN9A (0.69) SCN9ASENP1CCKBRKCNH2BRD4
SCHEMBL8241722 0.88 SCN9A (0.70) SCN9ASENP1CCKBRKCNH2BRD4
SCHEMBL6096123 0.86 CCKBR (0.69) SCN9ASENP1CCKBRKCNH2PSEN1
SCHEMBL6098837 0.86 CCKBR (0.69) SCN9ASENP1CCKBRKCNH2PSEN1
SCHEMBL4699390 0.84 HDAC3 (0.65) CCKBRKCNH2PSEN1PSEN2APH1B
SCHEMBL8241250 0.84 SCN9A (0.67) SCN9ASENP1CCKBRKCNH2BRD4
SCHEMBL10828856 0.83 CCKBR (0.67) SCN9ACCKBRCCKAR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1326849-B1 BENZODIAZEPINE DERIVATIVES AS INHIBITORS OF GAMMA SECRETASE MERCK SHARP & DOHME (GB) 2008-07-16 EP disclosed
US-7105509-B2 Benzodiazepine derivatives as APP modulators MERCK SHARP & DOHME LIMITED (GB) 2006-09-12 US disclosed
US-6995155-B2 Benzodiazepine derivatives as inhibitors of gamma secretase MERCK SHARP & DOHME LIMITED (GB) 2006-02-07 US disclosed
US-20040082572-A1 Benzodiazepine derivatives as app modulators MERCK SHARPE & DOHME LIMITED (GB) 2004-04-29 US disclosed
US-20040024203-A1 Benzodiazepine derivatives as inhibitors of gamma secretase MERCK SHARP & DOHME LTD. (GB) 2004-02-05 US disclosed
EP-1294702-A1 BENZODIAZEPINE DERIVATIVES AS APP MODULATORS MERCK SHARP & DOHME LTD. (GB) 2003-03-26 EP disclosed
WO-2001090084-A1 BENZODIAZEPINE DERIVATIVES AS APP MODULATORS MERCK SHARP & DOHME LIMITED (GB) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082572-A1 Benzodiazepine derivatives as app modulators BACE1, PSEN1, APP SCN9A 305/4885SENP1 528/4885CCKBR 642/4885
US-20040024203-A1 Benzodiazepine derivatives as inhibitors of gamma secretase BACE1, BACE2, PSEN1 SCN9A 337/4885SENP1 497/4885CCKBR 327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.